Overview

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Status:
Completed

Trial end date:
2020-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Collaborator:

Ovid Therapeutics Inc.